Axsome Therapeutics Inc. (AXSM)

Although fundamental investing wisdom tells us to "buy low," it may still be worthwhile to purchase shares of top companies following significant runs. Any point can be considered low -- even after ma...

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

Many investors love the "big mo." That's short for "big momentum.

Explore the exciting world of Axsome Therapeutics (AXSM -1.70%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends ...

Regardless of how stocks are performing right now, history tells us that the market tends to generate solid returns over long periods. Investors can do even better than the average market performance ...

Think of some of the biggest and most successful stocks on the market. Now, go back 20 or 30 years.

Axsome Therapeutics reported strong Q1 2025 earnings, with revenue and EPS beats driven by Auvelity and Sunosi, despite high SG&A expenses and net loss. Auvelity shows promising growth in the competit...

Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.

Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Piz...

Axsome Therapeutics Inc  AXSM on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the consensus of $119.87 million.